Unknown

Dataset Information

0

Tectorigenin inhibits RANKL-induced osteoclastogenesis via suppression of NF-?B signalling and decreases bone loss in ovariectomized C57BL/6.

ABSTRACT: Metabolism of bone is regulated by the balance between osteoblast-mediated bone formation and osteoclast-mediated bone resorption. Activation of osteoclasts could lead to osteoporosis. Thus, inhibiting the activity of osteoclasts becomes an available strategy for the treatment of osteoporosis. Tectorigenin is an extract of Belamcanda chinensis In the present study, the anti-osteoclastogenesis effects of tectorigenin were investigated in vitro and in vivo. The results showed preventive and therapeutic effects of tectorigenin at concentrations of 0, 10, 40, and 80 ?mol/L in the maturation and activation of osteoclasts. A signalling study also indicated that tectorigenin treatment reduces activation of NF-?B signalling in osteoclastogenesis. Animal experiment demonstrated that tectorigenin treatment (1-10 mg/kg, abdominal injection every 3 days) significantly inhibits bone loss in ovariectomized C57BL/6. Our data suggest that tectorigenin is a potential pharmacological choice for osteoporosis.

SUBMITTER: Ma C 

PROVIDER: S-EPMC6156464 | biostudies-other | 2018 Oct

REPOSITORIES: biostudies-other

Json Xml
altmetric image

Publications

Tectorigenin inhibits RANKL-induced osteoclastogenesis via suppression of NF-κB signalling and decreases bone loss in ovariectomized C57BL/6.

Ma Chiyuan C   Xu Kai K   Meng Jiahong J   Ran Jisheng J   Adel Abdo Moqbel Safwat S   Liu An A   Yan Shigui S   Wu Lidong L  

Journal of cellular and molecular medicine 20180731 10

Metabolism of bone is regulated by the balance between osteoblast-mediated bone formation and osteoclast-mediated bone resorption. Activation of osteoclasts could lead to osteoporosis. Thus, inhibiting the activity of osteoclasts becomes an available strategy for the treatment of osteoporosis. Tectorigenin is an extract of Belamcanda chinensis In the present study, the anti-osteoclastogenesis effects of tectorigenin were investigated in vitro and in vivo. The results showed preventive and therap  ...[more]

Similar Datasets

Unknown Sesamolin Protects Mice From Ovariectomized Bone Loss by Inhibiting Osteoclastogenesis and RANKL-Mediated NF-κB and MAPK Signaling Pathways.
| S-EPMC8237092 | biostudies-literature
Unknown Nepetin inhibits osteoclastogenesis by inhibiting RANKL-induced activation of NF-κB and MAPK signalling pathway, and autophagy.
| S-EPMC7754000 | biostudies-literature
Unknown Astilbin prevents bone loss in ovariectomized mice through the inhibition of RANKL-induced osteoclastogenesis.
| S-EPMC6850941 | biostudies-literature
Unknown Galangin suppresses RANKL-induced osteoclastogenesis via inhibiting MAPK and NF-κB signalling pathways.
| S-EPMC8178255 | biostudies-literature
Unknown Nitazoxanide, an Antiprotozoal Drug, Reduces Bone Loss in Ovariectomized Mice by Inhibition of RANKL-Induced Osteoclastogenesis.
| S-EPMC8696474 | biostudies-literature
Unknown A novel BRD4 inhibitor suppresses osteoclastogenesis and ovariectomized osteoporosis by blocking RANKL-mediated MAPK and NF-κB pathways.
| S-EPMC8236062 | biostudies-literature
Unknown Physalin D inhibits RANKL-induced osteoclastogenesis and bone loss via regulating calcium signaling.
| S-EPMC7118355 | biostudies-literature
Unknown Evodiamine inhibits RANKL-induced osteoclastogenesis and prevents ovariectomy-induced bone loss in mice.
| S-EPMC6307789 | biostudies-literature
Unknown Vindoline Inhibits RANKL-Induced Osteoclastogenesis and Prevents Ovariectomy-Induced Bone Loss in Mice.
| S-EPMC6987431 | biostudies-literature
Unknown Eudebeiolide B Inhibits Osteoclastogenesis and Prevents Ovariectomy-Induced Bone Loss by Regulating RANKL-Induced NF-?B, c-Fos and Calcium Signaling.
| S-EPMC7765597 | biostudies-literature